Literature DB >> 16434201

Anticancer activities of novel chalcone and bis-chalcone derivatives.

Aneta Modzelewska1, Catherine Pettit, Geetha Achanta, Nancy E Davidson, Peng Huang, Saeed R Khan.   

Abstract

A series of novel chalcones and bis-chalcones containing boronic acid moieties has been synthesized and evaluated for antitumor activity against the human breast cancer MDA-MB-231 (estrogen receptor-negative) and MCF7 (estrogen receptor-positive) cell lines and against two normal breast epithelial cell lines, MCF-10A and MCF-12A. These molecules inhibited the growth of the human breast cancer cell lines at low micromolar to nanomolar concentrations, with five of them (1-4, 9) showing preferential inhibition of the human breast cancer cell lines. Furthermore, bis-chalcone 8 exhibited a more potent inhibition of colon cancer cells expressing wild-type p53 than of an isogenic cell line that was p53-null.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434201     DOI: 10.1016/j.bmc.2006.01.003

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  45 in total

1.  Synthesis and antibacterial activity of some heterocyclic chalcone analogues alone and in combination with antibiotics.

Authors:  Thanh-Dao Tran; Thi-Thao-Nhu Nguyen; Tuong-Ha Do; Thi-Ngoc-Phuong Huynh; Cat-Dong Tran; Khac-Minh Thai
Journal:  Molecules       Date:  2012-06-01       Impact factor: 4.411

2.  Synthesis and biological evaluation of retinoid-chalcones as inhibitors of colon cancer cell growth.

Authors:  Cassia S Mizuno; Shiby Paul; Nanjoo Suh; Agnes M Rimando
Journal:  Bioorg Med Chem Lett       Date:  2010-10-14       Impact factor: 2.823

3.  An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent.

Authors:  Wang Yan; Chen Xiangyu; Li Ya; Wang Yu; Xu Feng
Journal:  Invest New Drugs       Date:  2019-02-11       Impact factor: 3.850

4.  Synthesis, electronic, and spectral properties of novel geranylated chalcone derivatives: a theoretical and experimental study.

Authors:  J C Espinoza-Hicks; J M Nápoles-Duarte; G V Nevárez-Moorillón; A Camacho-Dávila; L M Rodríguez-Valdez
Journal:  J Mol Model       Date:  2016-10-03       Impact factor: 1.810

5.  Liver S9 Fraction-Derived Metabolites of Curcumin Analogue UBS109.

Authors:  Terry W Moore; Shijun Zhu; Ryan Randolph; Mamoru Shoji; James P Snyder
Journal:  ACS Med Chem Lett       Date:  2014-01-10       Impact factor: 4.345

Review 6.  Molecular targeted approaches to cancer therapy and prevention using chalcones.

Authors:  Danielle D Jandial; Christopher A Blair; Saiyang Zhang; Lauren S Krill; Yan-Bing Zhang; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

7.  (E)-3-[4-(Dimethyl-amino)phen-yl]-1-(4-methyl-phen-yl)prop-2-en-1-one.

Authors:  Lei Wang; Li-Ying Ma; Yu-Ling Huang; Bai-Yu Zheng
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-12-16

8.  3-[4-(Dimethyl-amino)phen-yl]-1-(2-pyrrol-yl)prop-2-en-1-one.

Authors:  Si-Ping Tang; Dai-Zhi Kuang; Yong-Lan Feng; Wei Li; Zhi-Min Chen
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-05-21

9.  3-(4-Methoxy-phen-yl)-1-(2-pyrrol-yl)prop-2-en-1-one.

Authors:  Dong-Qing Li
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-09-13

10.  (E)-4-aryl-4-oxo-2-butenoic acid amides, chalcone-aroylacrylic acid chimeras: design, antiproliferative activity and inhibition of tubulin polymerization.

Authors:  Maja D Vitorović-Todorović; Aleksandra Erić-Nikolić; Branka Kolundžija; Ernest Hamel; Slavica Ristić; Ivan O Juranić; Branko J Drakulić
Journal:  Eur J Med Chem       Date:  2013-01-11       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.